A short consensus repeat-antibody construct (SCR-Ab) comprising (a) a complement factor H-derived short consensus repeat (fH-derived SCR); and (b) an antibody molecule that specifically recognizes or binds to a cancer cell, malignant cell or tumour cell, wherein said fH-derived SCR comprises a polypeptide that is capable of binding heparin, wherein said complement factor H-derived short consensus repeat (fH-derived SCR) and said antibody molecule are covalently linked or comprised in a single chain multi-functional polypeptide and wherein said fH-derived SCR is selected from the group consisting of: (i) a polypeptide encoded by the amino acid sequence comprised in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 30 or SEQ ID NO: 32; (ii) a polypeptide encoded by the amino acid sequence that is at least 60% identical to the amino acid sequence comprised in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 30 or SEQ ID NO: 32 and wherein said polypeptide is capable of binding heparin; (iii) a polypeptide encoded by the polynucleotide sequence as comprised in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29 or SEQ ID NO: 31; (iv) a polypeptide encoded by the complementary sequence of a polynucleotide that is able to hybridize with the polynucleotide as comprised in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29 or SEQ ID NO: 31 and wherein said polypeptide is capable of binding heparin; and (v) a polypeptide encoded by a nucleic acid molecule which is at least 60% identical to the nucleic acid sequence as comprised in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29 or SEQ ID NO: 31 and wherein said polypeptide is capable of binding heparin. (a) a complement factor H-derived short consensus repeat (fH-derived SCR); and (b) an antibody molecule that specifically recognizes or binds to a cancer cell, malignant cell or tumour cell, (i) a polypeptide encoded by the amino acid sequence comprised in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 30 or SEQ ID NO: 32; (ii) a polypeptide encoded by the amino acid sequence that is at least 60% identical to the amino acid sequence comprised in SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 30 or SEQ ID NO: 32 and wherein said polypeptide is capable of binding heparin; (iii) a polypeptide encoded by the polynucleotide sequence as comprised in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29 or SEQ ID NO: 31; (iv) a polypeptide encoded by the complementary sequence of a polynucleotide that is able to hybridize with the polynucleotide as comprised in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29 or SEQ ID NO: 31 and wherein said polypeptide is capable of binding heparin; and (v) a polypeptide encoded by a nucleic acid molecule which is at least 60% identical to the nucleic acid sequence as comprised in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29 or SEQ ID NO: 31 and wherein said polypeptide is capable of binding heparin.